Clinical Trial Update: Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay [NA]

View source ↗

Summary

Clinical trial update on using a high-throughput drug sensitivity assay to guide treatment for relapsed/refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Megakaryoblastic Leukemia
• Monocytic Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Snippet

Sponsor: University of Washington | Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | NA | Status: COMPLETED | Results posted: 2017-04-17